Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIncreased urination on Mounjaro is common and, in most cases, completely normal. It is not listed as a direct side effect of tirzepatide itself, but it is a well-recognised consequence of what the medicine does to your body in the early weeks of treatment. Understanding the difference matters. Mounjaro (tirzepatide) is a prescription-only medicine for weight management, and any persistent or troubling changes in urinary habits should always be discussed with your prescribing clinician.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Most people who notice they are visiting the bathroom more than usual assume the medicine is somehow acting on their kidneys or bladder directly. That is not what the evidence shows. Tirzepatide is a dual GIP and GLP-1 receptor agonist, it works primarily by signalling through gut-hormone pathways to reduce appetite and slow gastric emptying, as the NHS tirzepatide medicines page explains. The kidneys are not its target.
What is actually happening is more straightforward. When you eat significantly less (particularly fewer carbohydrates) your body starts burning through its glycogen stores. Glycogen is the form in which glucose is held in muscle and liver tissue, and it binds to water: roughly three grams of water for every gram of glycogen. As those stores are depleted, that water is released and excreted. If you are peeing a lot on Mounjaro, this glycogen-water release in the first one to two weeks of treatment is usually the reason.
This is the same mechanism behind the rapid initial weight loss many people notice in week one or two on tirzepatide. A good portion of it is water, not fat, worth knowing so you can interpret the scales sensibly as treatment progresses. You can read more about how tirzepatide works on our main medicine overview.
Mounjaro's appetite-suppressing effect can be striking, especially in the early weeks. Some people drop their calorie intake sharply without intending to. If that reduction is weighted towards starchy or sugary foods (bread, rice, pasta, snacks) the glycogen depletion happens faster, and with it a more noticeable flush of stored water.
This is not a sign that anything is wrong. It is, if anything, a signal that the medicine is doing its job. The practical issue is what comes alongside it. Nausea and vomiting are among the most commonly reported side effects of tirzepatide, particularly around dose changes. If you are on Mounjaro and peeing a lot while also losing fluids through nausea or loose stools, dehydration can creep up on you quietly.
Signs to take seriously: feeling dizzy when you stand, a persistent headache, very dark urine, or producing noticeably less urine despite drinking normally. These suggest your fluid intake is not keeping up with losses. The straightforward fix in mild cases is deliberate, steady hydration throughout the day. Sipping water regularly works better than drinking large amounts in one go, which can itself trigger nausea on tirzepatide. If symptoms feel severe or you cannot keep fluids down, contact your prescriber or NHS 111 the same day, do not wait.
Tirzepatide is also licensed for type 2 diabetes, and for people managing their blood sugar alongside weight, there is a separate mechanism worth knowing about. As tirzepatide improves insulin sensitivity and lowers blood glucose, the kidneys no longer need to excrete as much glucose in urine. This can actually reduce a specific kind of urinary urgency that some people with diabetes experience. So if you are diabetic and want to understand whether you should expect to pee a lot on Mounjaro, the picture is more nuanced than a simple yes or no.
On the other hand, if you are taking other glucose-lowering medicines alongside tirzepatide (particularly SGLT-2 inhibitors) those drugs work by deliberately increasing urinary glucose excretion, which does increase urine output. It is worth your prescriber reviewing your full medication list at each clinical check-in, particularly if urinary symptoms feel persistent or uncomfortable. A broader look at Mounjaro's clinical profile covers these interactions in more detail.
For those without diabetes, normal kidney function means tirzepatide does not directly change how the kidneys filter or produce urine. People who find they are peeing more on Mounjaro can generally expect this to settle back to their usual pattern within a few weeks, once glycogen stores have stabilised and the body has adjusted to the new eating pattern.
The question our prescribers hear regularly is: when does this stop being a quirk and start being a concern? The honest answer is that most cases of increased urination on tirzepatide are benign and self-limiting. But there are patterns that deserve a call rather than a Google.
Seek prompt medical attention if you notice: urine that is cloudy, has a strong unusual smell, or appears pink or red; burning or pain during urination (which points to a urinary tract infection rather than anything medication-related); urinating so frequently overnight that your sleep is significantly broken over more than a few days; or if increased thirst and urination appear together with unusual fatigue. The last combination, in particular, can occasionally signal that blood glucose is not settling as expected, and your prescriber will want to check that.
The MHRA Yellow Card scheme allows anyone to report suspected side effects from medicines, including tirzepatide, reporting unexpected urinary symptoms contributes to the ongoing safety monitoring of this relatively new treatment. If you have questions about how your current symptoms fit your treatment plan, our clinical team is reachable seven days a week. You can also browse frequently asked questions about Mounjaro for broader context, or learn more about how nume works before getting in touch.
Thinking about whether Mounjaro is the right option for you in the first place? Our weight-loss treatments page sets out what a free consultation involves, a named GPhC-registered prescriber reviews your details the same day, not software.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.